Papers associated with kcnh2

???displayGene.coCitedPapers???

???pagination.result.count???

???pagination.result.page??? ???pagination.result.prev??? 1 2 3 4 5 6 7 8 9 ???pagination.result.next???

Sort Newest To Oldest

Sort Oldest To Newest

	Inhibition of human ether-a-go-go-related gene K+ channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine., Choi SY, Koh YS, Jo SH., J Pharmacol Exp Ther. May 1, 2005; 313 (2): 888-95.
	Modulating effect of ginseng saponins on heterologously expressed HERG currents in Xenopus oocytes., Kim CS, Son SJ, Kim HS, Kim YD, Lee KS, Jeon BH, Kim KJ, Park JK, Park JB., Acta Pharmacol Sin. May 1, 2005; 26 (5): 551-8.
	The influence of extracellular acidosis on the effect of IKr blockers., Lin C, Ke X, Cvetanovic I, Ranade V, Somberg J., J Cardiovasc Pharmacol Ther. March 1, 2005; 10 (1): 67-76.
	QTc prolongation by grapefruit juice and its potential pharmacological basis: HERG channel blockade by flavonoids., Zitron E, Scholz E, Owen RW, Lück S, Kiesecker C, Thomas D, Kathöfer S, Niroomand F, Kiehn J, Kreye VA, Katus HA, Schoels W, Karle CA., Circulation. February 22, 2005; 111 (7): 835-8.
	Effect of beta-adrenoceptor blockers on human ether-a-go-go-related gene (HERG) potassium channels., Dupuis DS, Klaerke DA, Olesen SP., Basic Clin Pharmacol Toxicol. February 1, 2005; 96 (2): 123-30.
	Structure-function studies of the outer mouth and voltage sensor domain of hERG., Tseng GN, Guy HR., Novartis Found Symp. January 1, 2005; 266 19-35; discussion 35-45.
	A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels., Lin C, Cvetanovic I, Ke X, Ranade V, Somberg J., Am J Ther. January 1, 2005; 12 (4): 328-36.
	Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action., Kiesecker C, Zitron E, Lück S, Bloehs R, Scholz EP, Kathöfer S, Thomas D, Kreye VA, Katus HA, Schoels W, Karle CA, Kiehn J., Naunyn Schmiedebergs Arch Pharmacol. December 1, 2004; 370 (6): 423-35.
	Salt bridges and gating in the COOH-terminal region of HCN2 and CNGA1 channels., Craven KB, Zagotta WN., J Gen Physiol. December 1, 2004; 124 (6): 663-77.
	Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine., Sánchez-Chapula JA, Navarro-Polanco RA, Sanguinetti MC., Naunyn Schmiedebergs Arch Pharmacol. December 1, 2004; 370 (6): 484-91.
	Gating charges in the activation and inactivation processes of the HERG channel., Zhang M, Liu J, Tseng GN., J Gen Physiol. December 1, 2004; 124 (6): 703-18.
	Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X)., Thomas D, Hammerling BC, Wimmer AB, Wu K, Ficker E, Kuryshev YA, Scherer D, Kiehn J, Katus HA, Schoels W, Karle CA., Cardiovasc Res. December 1, 2004; 64 (3): 467-76.
	Activation of cardiac human ether-a-go-go related gene potassium currents is regulated by alpha(1A)-adrenoceptors., Thomas D, Wu K, Wimmer AB, Zitron E, Hammerling BC, Kathöfer S, Lueck S, Bloehs R, Kreye VA, Kiehn J, Katus HA, Schoels W, Karle CA., J Mol Med (Berl). December 1, 2004; 82 (12): 826-37.
	Identification and characterisation of a novel KCNQ1 mutation in a family with Romano-Ward syndrome., Zehelein J, Thomas D, Khalil M, Wimmer AB, Koenen M, Licka M, Wu K, Kiehn J, Brockmeier K, Kreye VA, Karle CA, Katus HA, Ulmer HE, Schoels W., Biochim Biophys Acta. November 5, 2004; 1690 (3): 185-92.
	The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping., Witchel HJ, Dempsey CE, Sessions RB, Perry M, Milnes JT, Hancox JC, Mitcheson JS., Mol Pharmacol. November 1, 2004; 66 (5): 1201-12.
	Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels., Gögelein H, Brendel J, Steinmeyer K, Strübing C, Picard N, Rampe D, Kopp K, Busch AE, Bleich M., Naunyn Schmiedebergs Arch Pharmacol. September 1, 2004; 370 (3): 183-92.
	Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone., Zitron E, Kiesecker C, Scholz E, Lück S, Bloehs R, Kathöfer S, Thomas D, Kiehn J, Kreye VA, Katus HA, Schoels W, Karle CA., Naunyn Schmiedebergs Arch Pharmacol. August 1, 2004; 370 (2): 146-56.
	Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects., Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S., Br J Pharmacol. August 1, 2004; 142 (8): 1300-8.
	Structural determinants of HERG channel block by clofilium and ibutilide., Perry M, de Groot MJ, Helliwell R, Leishman D, Tristani-Firouzi M, Sanguinetti MC, Mitcheson J., Mol Pharmacol. August 1, 2004; 66 (2): 240-9.
	Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG., Hayashi K, Shimizu M, Ino H, Yamaguchi M, Terai H, Hoshi N, Higashida H, Terashima N, Uno Y, Kanaya H, Mabuchi H., Clin Sci (Lond). August 1, 2004; 107 (2): 175-82.
	Molecular basis of slow activation of the human ether-a-go-go related gene potassium channel., Subbiah RN, Clarke CE, Smith DJ, Zhao J, Campbell TJ, Vandenberg JI., J Physiol. July 15, 2004; 558 (Pt 2): 417-31.
	Comparison of kinetic properties of quinidine and dofetilide block of HERG channels., Tsujimae K, Suzuki S, Yamada M, Kurachi Y., Eur J Pharmacol. June 16, 2004; 493 (1-3): 29-40.
	Activation properties of Kv4.3 channels: time, voltage and [K+]o dependence., Wang S, Bondarenko VE, Qu Y, Morales MJ, Rasmusson RL, Strauss HC., J Physiol. June 15, 2004; 557 (Pt 3): 705-17.
	Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action., Thomas D, Hammerling BC, Wu K, Wimmer AB, Ficker EK, Kirsch GE, Kochan MC, Wible BA, Scholz EP, Zitron E, Kathöfer S, Kreye VA, Katus HA, Schoels W, Karle CA, Kiehn J., Br J Pharmacol. June 1, 2004; 142 (3): 485-94.
	Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels., Yang BF, Xu DH, Xu CQ, Li Z, Du ZM, Wang HZ, Dong DL., Acta Pharmacol Sin. May 1, 2004; 25 (5): 554-60.
	Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels., Dong DL, Li Z, Wang HZ, Du ZM, Song WH, Yang BF., Basic Clin Pharmacol Toxicol. May 1, 2004; 94 (5): 209-12.
	Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents., Gessner G, Zacharias M, Bechstedt S, Schönherr R, Heinemann SH., Mol Pharmacol. May 1, 2004; 65 (5): 1120-9.
	Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin., Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA., Naunyn Schmiedebergs Arch Pharmacol. May 1, 2004; 369 (5): 462-72.
	Block of HERG human K(+) channel and IKr of guinea pig cardiomyocytes by chlorpromazine., Lee SY, Choi SY, Youm JB, Ho WK, Earm YE, Lee CO, Lee CO, Jo SH., J Cardiovasc Pharmacol. May 1, 2004; 43 (5): 706-14.
	Compound mutations: a common cause of severe long-QT syndrome., Westenskow P, Splawski I, Timothy KW, Keating MT, Sanguinetti MC., Circulation. April 20, 2004; 109 (15): 1834-41.
	BmTx3, a scorpion toxin with two putative functional faces separately active on A-type K+ and HERG currents., Huys I, Xu CQ, Wang CZ, Vacher H, Martin-Eauclaire MF, Chi CW, Tytgat J., Biochem J. March 15, 2004; 378 (Pt 3): 745-52.
	Physicochemical features of the HERG channel drug binding site., Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC., J Biol Chem. March 12, 2004; 279 (11): 10120-7.
	Differential recovery of action potential duration and HERG currents from the effects of two methanesulfonamide class III antiarrhythmic agents, KCB-328 and dofetilide., Lee K, Park JB, Jeon BH, Kim KJ, Ryu PD, Kwon LS, Kim HY., J Cardiovasc Pharmacol. November 1, 2003; 42 (5): 648-55.
	Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine., Scholz EP, Zitron E, Kiesecker C, Lueck S, Kathöfer S, Thomas D, Weretka S, Peth S, Kreye VA, Schoels W, Katus HA, Kiehn J, Karle CA., Naunyn Schmiedebergs Arch Pharmacol. November 1, 2003; 368 (5): 404-14.
	Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels., Thomas D, Kathofer S, Zhang W, Wu K, Wimmer AB, Zitron E, Kreye VA, Katus HA, Schoels W, Karle CA, Kiehn J., Br J Pharmacol. November 1, 2003; 140 (5): 996-1002.
	Gating currents associated with intramembrane charge displacement in HERG potassium channels., Piper DR, Varghese A, Sanguinetti MC, Tristani-Firouzi M., Proc Natl Acad Sci U S A. September 2, 2003; 100 (18): 10534-9.
	Regulation of HERG potassium channel activation by protein kinase C independent of direct phosphorylation of the channel protein., Thomas D, Zhang W, Wu K, Wimmer AB, Gut B, Wendt-Nordahl G, Kathöfer S, Kreye VA, Katus HA, Schoels W, Kiehn J, Karle CA., Cardiovasc Res. July 1, 2003; 59 (1): 14-26.
	Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen., Thomas D, Gut B, Karsai S, Wimmer AB, Wu K, Wendt-Nordahl G, Zhang W, Kathöfer S, Schoels W, Katus HA, Kiehn J, Karle CA., Naunyn Schmiedebergs Arch Pharmacol. July 1, 2003; 368 (1): 41-8.
	[Electropharmacological assessment of the risk of drug-induced long-QT syndrome using native cardiac cells and cultured cells expressing HERG channels]., Nakaya H., Nihon Yakurigaku Zasshi. June 1, 2003; 121 (6): 384-92.
	The antipsychotic drug chlorpromazine inhibits HERG potassium channels., Thomas D, Wu K, Kathöfer S, Katus HA, Schoels W, Kiehn J, Karle CA., Br J Pharmacol. June 1, 2003; 139 (3): 567-74.
	Negative charges in the transmembrane domains of the HERG K channel are involved in the activation- and deactivation-gating processes., Liu J, Zhang M, Jiang M, Tseng GN., J Gen Physiol. June 1, 2003; 121 (6): 599-614.
	Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain., Sănchez-Chapula JA, Ferrer T, Navarro-Polanco RA, Sanguinetti MC., Mol Pharmacol. May 1, 2003; 63 (5): 1051-8.
	BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1., Zhang M, Korolkova YV, Liu J, Jiang M, Grishin EV, Tseng GN., Biophys J. May 1, 2003; 84 (5): 3022-36.
	RNA interference reveals that endogenous Xenopus MinK-related peptides govern mammalian K+ channel function in oocyte expression studies., Anantharam A, Lewis A, Panaghie G, Gordon E, McCrossan ZA, Lerner DJ, Abbott GW., J Biol Chem. April 4, 2003; 278 (14): 11739-45.
	Drug- and mutagenesis-induced changes in the selectivity filter of a cardiac two-pore background K+ channel., Hajdú P, Ulens C, Panyi G, Tytgat J., Cardiovasc Res. April 1, 2003; 58 (1): 46-54.
	Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency., Ishii K, Nagai M, Takahashi M, Endoh M., Cardiovasc Res. March 1, 2003; 57 (3): 651-9.
	[K(+)](o)-dependent change in conformation of the HERG1 long QT mutation N629D channel results in partial reversal of the in vitro disease phenotype., Teng GQ, Lees-Miller JP, Duan Y, Li BT, Li P, Duff HJ., Cardiovasc Res. March 1, 2003; 57 (3): 642-50.
	Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5., Peukert S, Brendel J, Pirard B, Brüggemann A, Below P, Kleemann HW, Hemmerle H, Schmidt W., J Med Chem. February 13, 2003; 46 (4): 486-98.
	C-terminal domains implicated in the functional surface expression of potassium channels., Jenke M, Sánchez A, Monje F, Stühmer W, Weseloh RM, Pardo LA., EMBO J. February 3, 2003; 22 (3): 395-403.
	Interaction between tetraethylammonium and permeant cations at the inactivation gate of the HERG potassium channel., Shimizu H, Toyoshima C, Oiki S., Jpn J Physiol. February 1, 2003; 53 (1): 25-34.

???pagination.result.page??? ???pagination.result.prev??? 1 2 3 4 5 6 7 8 9 ???pagination.result.next???